RecruitingNCT06190821DuodenalUpdated Jan 5, 2024

Hydrodissection of the Hepatoduodenal Ligament

An observational study in Hepatic Lesions, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by University Hospital, Strasbourg, France · Observational

From the registry’s dates

Primary completion was expected by Feb 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
Started Jul 2022; still recruiting 4 years 2 months later.

Study type: Observational
Model: Case-only
Time perspective: Retrospective
Enrollment: 13
Ages: 18 Years and older
Sex: All

Study summary

Percutaneous treatment of liver lesions adjacent to the duodenum exposes the duodenum to the risk of thermal injury, limiting removal and oncologic outcome. In this study the investigators investigate the feasibility of hepato duodenal ligament dissection in the percutaneous treatment of liver lesions adjacent to the duodenum.

Conditions studied

Hepatic Lesions

Keywords

hepatic lesions
liver lesions
duodenum
hepato duodenal ligament

In context

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 966 studies on the registry; 342 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Sampling method: Non-probability sample

Study population

Major subject (≥18 years of age) who underwent percutaneous ablation of primary or secondary liver lesions at HUS that required per-procedure hepatoduodenal ligament hydrodissection in the interventional imaging department of the New Civil Hospital from January 2019 to July 2022.

Inclusion criteria

Major subject (≥18 years of age)
Subject who underwent percutaneous ablation of primary or secondary liver lesions at HUS that required per-procedure hepatoduodenal ligament hydrodissection in the interventional imaging department of the New Civil Hospital from January 2019 to July 2022.
Subject who has not expressed opposition to the reuse of their data for the purpose of this research.

Exclusion criteria

Exclusion Criteria:

Opposition to the reuse of his/her data for the purpose of scientific research.

Study design

Observational model: Case-only
Time perspective: Retrospective
Enrollment: 13 participants (estimated)
Patient registry: No

What researchers measure

Primary outcomes

Retrospective description of the hepatoduodenal ligament dissection in the percutaneous treatment of liver lesions adjacent to the duodenum
This study is retrospective
Time frame: Files analysed retrospectively from January 01, 2019 to July 31, 2022 will be examined

Study locations

1 of 1 sites recruiting

Service Imagerie interventionnelle oncologique et viscérale - CHU de Strasbourg - France
Strasbourg, 67091, France
- Julien GARNON, MD, PhD · Contact · julien.garnon@chru-strasbourg.fr · 33 3.69.55.03.04
- Julien GARNON, MD, PhD · Principal investigator
- Guillaume LOTZ, MD · Principal investigator
Recruiting

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT06190821
Lead sponsor: University Hospital, Strasbourg, France
Responsible party: Sponsor
First posted: Jan 5, 2024
Start date: Jul 20, 2022
Primary completion: Feb 2025 (estimated)
Completion: Feb 20, 2025 (estimated)
Last update: Jan 5, 2024

Study contacts

Julien GARNON, MD

Contact

julien.garnon@chru-strasbourg.fr

33 3.69.55.03.04

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

University Hospital, Strasbourg, France

Start the discussion